Predicting Febrile Neutropenia Risk After Chemotherapy
Author Information
Author(s): Ray-Coquard I, Borg C, Bachelot Th, Sebban C, Philip I, Clapisson G, Le Cesne A, Biron P, Chauvin F, Blay J Y
Primary Institution: Centre L. Bérard, Lyon, France
Hypothesis
Can baseline and early lymphopenia predict the risk of febrile neutropenia after chemotherapy?
Conclusion
Baseline day 1 lymphopenia is an independent risk factor for febrile neutropenia in patients undergoing chemotherapy.
Supporting Evidence
- Febrile neutropenia is a common and serious complication of chemotherapy.
- Day 1 lymphocyte count can help identify patients at high risk for febrile neutropenia.
- Patients with both high-risk chemotherapy and low day 1 lymphocyte counts had a 44% incidence of febrile neutropenia.
Takeaway
Doctors can tell if a patient might get sick after chemotherapy by checking their blood cell count before treatment starts.
Methodology
The study analyzed data from 950 patients treated with chemotherapy, focusing on day 1 and day 5 lymphocyte counts to assess risk factors for febrile neutropenia.
Potential Biases
Potential bias due to exclusion of patients with certain conditions and reliance on historical data.
Limitations
The study may not generalize to all cancer patients as it focused on those treated in specific centers.
Participant Demographics
Patients were aged 17 and older, with a mix of genders and various cancer types.
Statistical Information
P-Value
0.052
Confidence Interval
1.49–4.8
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website